Literature DB >> 18982002

The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling.

J M Bessa1, D Ferreira, I Melo, F Marques, J J Cerqueira, J A Palha, O F X Almeida, N Sousa.   

Abstract

The mechanisms underlying the initiation/onset of, and the recovery from, depression are still largely unknown; views that neurogenesis in the hippocampus may be important for the pathogenesis and amelioration of depressive symptoms have gained currency over the years although the original evidence has been challenged. In this study, an unpredictable chronic mild stress protocol was used to induce a depressive-like phenotype in rats. In the last 2 weeks of stress exposure, animals were treated with the antidepressants fluoxetine, imipramine, CP 156,526 or SSR 1494515, alone or combined with methylazoxymethanol, a cytostatic agent used to arrest neurogenesis. We found that antidepressants retain their therapeutic efficacy in reducing both measured indices of depression-like behavior (learned helplessness and anhedonia), even when neurogenesis is blocked. Instead, our experiments suggest re-establishment of neuronal plasticity (dendritic remodeling and synaptic contacts) in the hippocampus and prefrontal cortex, rather than neurogenesis, as the basis for the restoration of behavioral homeostasis by antidepressants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18982002     DOI: 10.1038/mp.2008.119

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  225 in total

Review 1.  Depression, antidepressants, and neurogenesis: a critical reappraisal.

Authors:  Nicola D Hanson; Michael J Owens; Charles B Nemeroff
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Extracellular signal-regulated kinase 2 signaling in the hippocampal dentate gyrus mediates the antidepressant effects of testosterone.

Authors:  Nicole Carrier; Mohamed Kabbaj
Journal:  Biol Psychiatry       Date:  2012-01-20       Impact factor: 13.382

3.  Using causal models to distinguish between neurogenesis-dependent and -independent effects on behaviour.

Authors:  Stanley E Lazic
Journal:  J R Soc Interface       Date:  2011-09-28       Impact factor: 4.118

Review 4.  Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date.

Authors:  Daniel C Mathews; Ioline D Henter; Carlos A Zarate
Journal:  Drugs       Date:  2012-07-09       Impact factor: 9.546

5.  3β-Methoxy-pregnenolone (MAP4343) as an innovative therapeutic approach for depressive disorders.

Authors:  Massimiliano Bianchi; Etienne-Emile Baulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-19       Impact factor: 11.205

Review 6.  Remodeling of axo-spinous synapses in the pathophysiology and treatment of depression.

Authors:  P Licznerski; R S Duman
Journal:  Neuroscience       Date:  2012-10-02       Impact factor: 3.590

7.  Neuronal plasticity and antidepressant actions.

Authors:  Eero Castrén; René Hen
Journal:  Trends Neurosci       Date:  2013-02-01       Impact factor: 13.837

8.  Novel antidepressant effects of Paeonol alleviate neuronal injury with concomitant alterations in BDNF, Rac1 and RhoA levels in chronic unpredictable mild stress rats.

Authors:  Xiu-Ling Zhu; Jing-Jing Chen; Fei Han; Chuan Pan; Ting-Ting Zhuang; Ya-Fei Cai; Ya-Ping Lu
Journal:  Psychopharmacology (Berl)       Date:  2018-05-12       Impact factor: 4.530

Review 9.  The involvement of microRNAs in major depression, suicidal behavior, and related disorders: a focus on miR-185 and miR-491-3p.

Authors:  Gianluca Serafini; Maurizio Pompili; Katelin F Hansen; Karl Obrietan; Yogesh Dwivedi; Noam Shomron; Paolo Girardi
Journal:  Cell Mol Neurobiol       Date:  2013-11-09       Impact factor: 5.046

10.  Impaired hippocampal neuroligin-2 function by chronic stress or synthetic peptide treatment is linked to social deficits and increased aggression.

Authors:  Michael A van der Kooij; Martina Fantin; Igor Kraev; Irina Korshunova; Jocelyn Grosse; Olivia Zanoletti; Ramon Guirado; Clara Garcia-Mompó; Juan Nacher; Michael G Stewart; Vladimir Berezin; Carmen Sandi
Journal:  Neuropsychopharmacology       Date:  2013-11-11       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.